Recommendations has been made by the Indian Council of Medical Research (ICMR) for use of hydroxy-chloroquine for healthcare workers involved in the care of suspected or confirmed Covid-19 cases and the asymptomatic household contacts of lab-confirmed cases as a preventive treatment measure.
Bengal Chemicals, a PSU pharma company and Pharmaceuticals said it can provide only a maximum of 10 lakh hydroxy-chloroquine tablets due to the shortage of a key component, Active Pharmaceutical Ingredient (API).
Bengal Chemicals is possibly the only company from this part of the country having the capacity to produce hydroxy-chloroquine.
BPCL managing director PM Chandraiah told , “Whatever raw material (API) we have that can be good for only 10 lakh malaria tablets (having hydroxy-chloroquine),”
API is the term used to refer to the biologically active component of a drug product such as tablet, capsule.
India imports 80 per cent of API from China, from where the novel coronavirus originated, to meet its requirements.
“In India, only the private sector IPCA produces API and we had been told that we are in the queue and our turn will come in May-June,” he further said.
